Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07270835 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
For patients who met the inclusion criteria, treatment regimens were administered: Rituximab 375 mg/m², intravenously, once weekly for 4 weeks. Zanubrutinib 160 mg, orally, twice daily for 4 weeks. Combined drugs: prednisone 100 mg/m²/d, orally, d1-5; Ruxolitinib 15mg bid orally; With/without emapalumab as appropriate.
Trial Details
NCT Number NCT07270835
Lead Sponsor The First Affiliated Hospital of Soochow University
Conditions
(from sponsor)		 Hemophagocytic Lymphohistiocytosis, B Cell Lymphoma
Related terms Lymphohistiocytosis, Hemophagocytic, Lymphoma, B-Cell
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov